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Preventing and reversing mitochondrial dysfunction in the neuron is a widely pursued 
objective in neurodegeneration research. Neurons rely on mitochondria to synthesize 
ATP, and a large body of evidence suggests that mitochondrial regulation of oxidative 
stress and Ca2+ homeostasis is essential for controlling the neurodegenerative process. 
The molecular mechanisms that give rise to defective activities of the mitochondrial 
electron transport chain (ETC) complexes present in brain disorders such as Parkinson’s 
disease and Alzheimer’s disease remain unknown. However, aberrant aggregation of 
proteins, such as a-synuclein and ß-amyloid, are known to interact with ETC complexes 
and reduce their activities. Neurotoxins, such as the Parkinsonian-inducing compound, 1-
methyl-4-phenylpyridinium (MPP+), have been invaluable agents in exploring the 
relationship between oxidative phosphorylation, Ca2+ homeostasis and reactive oxygen 
species (ROS) in the dopaminergic neuron. Amongst the important regulators of 
mitochondrial ROS are superoxide dismutase and glutathione peroxidase, as they control 
superoxide and peroxide levels respectively. Recently, the peroxiredoxin antioxidant 
enzyme family was found to scavenge peroxide and, hence, to control oxidative stress in 
neurons through the use of redox active cysteine(s) within their active site, that becomes 
oxidized to sulphenic acid. The oxidized peroxiredoxin in turn may be recycled to a 
reduced state by interacting with thioredoxins. One of the peroxiredoxins that localizes 
both in mitochondria and cytoplasm, peroxiredoxin 5 (PRDX5), reacts more efficiently 
with peroxynitrite and organic peroxides than other peroxiredoxins. Peroxynitrite 
(ONOO_) plays a critical role in mitochondrial ETC damage and regulation of this highly 
reactive nitrogen species may be neuroprotective. (Bolaños and Heales 2010). In a 
previous study, it was found that PRDX5-deficient SH-SY5Y neuroblastoma cells are 
more vulnerable to the Parkinsonian-inducing toxin MPP+ (De Simoni et al. 2008); 
however, the precise molecular mechanism whereby PRDX5 could exert neuroprotection 
remained elusive. In the article by De Simoni, 2013 in the Journal of Neurochemistry 
(DOI: 10.1111/jnc.12117), the authors followed up these observations using the inverse 
strategy of stably expressing the human mitochondrial form of PRDX5 in SH-SY5Y cells. 
In a comprehensive series of experiments, the involvement of PRDX5 in linking 
mitochondrial redox signalling with endoplasmic reticulum (ER)-mitochondrial Ca2+ 
dynamics was monitored in response to the Parkinsonian-inducing toxin, MPP+. They 
found that PRDX5 reduced MPP+-induced cytotoxicity, as assayed by LDH release, ATP, 
ROS and 3-nitrotyrosine production (as an index of reactive nitrogen species), 
suggesting a role for this isoform in controlling the rate of apoptosis in these cells. This 
antiapoptotic effect was confirmed by experiments showing the reversal of MPP+-
induced changes in mitochondrial DNA (mtDNA) damage, caspases-3 and -9 activation 
and apoptotic nuclei. Further experiments revealed the ability of PRDX5 to abolish the 
increase in intracellular Ca2+, prevent calpain activation and markedly reduce the 
production of pro-apoptotic tBax in MPP+-treated cells. Next, the authors explored the 
MPP+-induced effects on Ca2+ dynamics by using nimodipine to inhibit L-type voltage–
dependent calcium channels in the plasma membrane, dantrolene to inhibit ryanodine 
receptors (RyRs) in the ER and 2-aminoethoxy diphenyl borate to inhibit inositol-1,4, 5-
trisphosphate receptors (IP3Rs) in the ER.  
The results showed that 2-aminoethoxy diphenyl borate significantly counteracted loss of 
cell viability in response to MPP+ as well as nearly totally preventing the increase in 
cytosolic Ca2+, similar to overexpression of mitochondrial PRDX5. Thus, mitochondrial 
PRDX5 is revealed as a viable target for neuroprotection through its ability to control 
ROS/reactive nitrogen species generation as well as Ca2+ dysregulation. The results of 
De Simoni and colleagues (De Simoni et al. 2013) fit within the interesting growing field 
of peroxiredoxins being regulators of dopaminergic degeneration in Parkinson’s disease 
(PD). Thus, a role for peroxiredoxin in this disorder has been suggested to involve 
phosphorylation of the PRDX2 isoform in nigral neurons in post-mortem tissue from PD 
patients (Qu et al. 2007). PRDX1 over-expression protects against 6-hydroxydopamine 
(6-OHDA)-induced Parkinsonism in cell culture models (Lee et al. 2006). Interestingly, 
the relatively low levels of PRDX5 in dopaminergic neurons may be an important reason 
why these neurons are less resistant to toxic stress than other neurons in the brain. 
Likewise, these findings raise a number of interesting possibilities. For example, follow-up 
experiments should now focus on the ability of PRDX5 to prevent neurotoxicity in both 
primary neurons and in PD-patient-specific iPS-derived dopaminergic neurons. Overall, 
the fact that PRDX5 clearly affects Ca2+ dynamics is also important in the light of the 
new anti-Parkinsonian therapeutics that regulate Ca2+ transport. The further involvement 
of PRDX5 in regulating Ca2+ dynamics in dopaminergic neurons remains to be seen. A 
number of tantalizing implications come to mind in light of recent research on 
mitochondrial transport and Ca2+ dynamics in the neuron. The recent focus on 
mitochondrial fusion and fission events, and interactions with the ER has opened up an 
exciting area of neuronal biology. The fact that PRDX5 controls redox signalling in the 
mitochondrion and Ca2+ dynamics suggests it may have a role in post-translation 
modification of key mitochondrial fusion/fission and transport proteins. The effect of 
mitochondrial PRDX5 on complex I activity must be clarified as this defect of the ETC is 
an important observation in idiopathic PD (Schapira et al. 1989); the possibility that 
PRDX5-related redox signalling may control individual complex I subunit activity might be 
relevant to the disease pathology. Finally, mitochondrial heterogeneity within neurons 
and other cell types in the brain may relate to PRDX5 subcellular distribution. 
Mitochondria that reside in the nerve terminal region in the pre-synaptic neuron are 
known to have lower complex I energy thresholds than mitochondria from other origin 
(Telford et al. 2009), and seem to be more susceptible to neurotoxin-induced damage. 
Therefore, it would be interesting to analyse such mitochondria for the abundance of 
PRDX5 and other peroxiredoxins. 
 
 
 
 
